Anti-tumor Effects Of Aglaroxin C In H22 Tumor-bearing Mice And Its Influence On Mice Organs

BackgroundPrimary liver cancer?PLC?is the third most common malignant tumor and the second leading cause of death in China,which seriously threatens the lives and health of Chinese people^[1].Most patients with advanced primary liver cancer have lost the opportunity of surgery and local treatments such as radiofrequency ablation.At present,the commonly used molecular targeting drugs and chemotherapeutic drugs have the disadvantages of prolonging the survival time and many side effects,it is urgent to develop new molecular targeting drugs^[2,3].Rocaglamide A is cyclopenta[b]-benzofuran-type compound isolated from the plant genus Aglaia?family Meliaceae?and shows possess anti-tumor activities^[4-6].Aglaroxin C is one of the Rocaglamide A derivatives,which is first synthesized by Professor john porco jr.team at the Boston University Center for Molecular Discovery?BU-CMD?^[7].At present,there is no report on the efficacy of its antihepatoma and toxicological evaluation in vivo.ObjectiveTo investigate the antitumor effects of Aglaroxin C in H22 tumor-bearing mice and its influence on mice organs at the experimental dose.MethodsThe solid tumor model was established by subcutaneously transplanting H22 cells into Balb/c mice.The mice were subsequently divided into five groups as follows:Group??tail vein administration of physiological saline,negative control group?,Group II?tail vein administration of 0.1mg aglaroxin C?.Group??intratumoral administration of physiological saline,negative control group?,Group IV?intratumoral administration of 0.05mg aglaroxin C?,Group V?intratumoral administration of 0.1mg aglaroxin C?.Each group had 5 mice.The mice in the control group were treated with physiological saline whereas the mice in other groups were given drugs at indicated time point for a total of 4 times.The body weight of mice was measured daily.24 hours after the last drug injection,all mice were sacrificed.Main organs and tumor tissues were collected and weighed.The tumor inhibition rate and organ coefficient were calculated.Pathological section,HE staining and observation under light microscope were also performed.Results1.The mice in the administration group and the control group had normal activity,luster,normal eating and drinking water,no abnormal changes in stool and urine,and no death.2.The mean tumor weights?g?in the different groups were:?2.11±0.5;II 1.59±0.14;III 2.30±0.64;IV 1.66±0.12;?1.06±0.14?in grams?.The tumor weight from group?was significantly less than that of group??t=5.61,P<0.01?.There was also significant differences in tumor weight between group?,?and??F=13.12,P<0.01?.The tumor inhibition rates of group?,?and?were 24.64%,27.83%,53.91%respectively.3.Necrotic tumor cells in Aglaroxin C treated groups increased significantly.4.Dody weight changes between groups were not statistically significant?F=0.98;P>0.05?.5.Micromorphological changes of organs showed no difference between the control and experimental groups.6.Furthermore,there was no significant difference in organ coefficient between the control and experimental groups?P>0.05?.ConclusionAglaroxin C potently inhibited the proliferation of mouse hepatoma H22 cells in the mice tumor model.Aglaroxin C displayed no influence on mice organs at the experimental dose.